Case Study

MAbxience Optimizes And Accelerates Downstream Biosimilar Process Development

Source: Cytiva
MAbxience Optimizes And Accelerates Downstream Biosimilar Process Development

Biosimilars represent an innovative solution that can benefit both patients and healthcare systems by reducing the burden of rising treatment costs. To improve the availability many countries are implementing strategies to establish their own production capacity. To support this development, mAbxience, a Spanish biotechnology company, is committed to provide the manufacturing of high- quality products and processes that meet regulatory and technical requirements in all countries where it operates.

This case study demonstrates the optimization of the downstream purification process to improve product purity and recovery of the biosimilar Fc-fusion protein. The optimization work was conducted by Fast Trak scientists. Process optimization focused  on improving the affinity chromatography (AF) capture step as well as the intermediate purification and polishing steps, using hydrophobic interaction chromatography (HIC) and anion exchange chromatography (AIEX), respectively, keeping the same process materials.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Biosimilar Development? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: